-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Critical Contrast: Allbirds (NASDAQ:BIRD) and Silo Pharma (NASDAQ:SILO)
Critical Contrast: Allbirds (NASDAQ:BIRD) and Silo Pharma (NASDAQ:SILO)
Allbirds (NASDAQ:BIRD – Get Rating) and Silo Pharma (NASDAQ:SILO – Get Rating) are both small-cap retail/wholesale companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.
Institutional & Insider Ownership
33.1% of Allbirds shares are held by institutional investors. Comparatively, 11.6% of Silo Pharma shares are held by institutional investors. 31.9% of Allbirds shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Get Allbirds alerts:Profitability
This table compares Allbirds and Silo Pharma's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Allbirds | -27.97% | -19.91% | -16.36% |
| Silo Pharma | -4,622.68% | -35.46% | -31.26% |
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Allbirds and Silo Pharma, as reported by MarketBeat.com.| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Allbirds | 0 | 7 | 6 | 0 | 2.46 |
| Silo Pharma | 0 | 0 | 0 | 0 | N/A |
Allbirds presently has a consensus price target of $7.15, suggesting a potential upside of 121.48%. Given Allbirds' higher possible upside, equities research analysts clearly believe Allbirds is more favorable than Silo Pharma.
Earnings and Valuation
This table compares Allbirds and Silo Pharma's gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Allbirds | $310.81 million | 1.55 | -$45.37 million | ($0.61) | -5.30 |
| Silo Pharma | $70,000.00 | 137.26 | $3.90 million | N/A | N/A |
Silo Pharma has lower revenue, but higher earnings than Allbirds.
Summary
Allbirds beats Silo Pharma on 8 of the 10 factors compared between the two stocks.
About Allbirds
(Get Rating)
Allbirds, Inc. manufactures and sells footwear and apparel products for men and women. It offers shoes, such as running shoes, everyday sneakers, high-tops, slip-ons, boat shoes, flats, weather repellent shoes, and sandals. The company's apparel products include activewear, tops, bottoms, dresses, sweaters, underwear, and socks. It sells its products through its retail stores in the United States and internationally, as well as online. Allbirds, Inc. was formerly known as Bozz, Inc. Allbirds, Inc. was incorporated in 2015 and is based in San Francisco, California.
About Silo Pharma
(Get Rating)
Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in merging traditional therapeutics with psychedelic research. It seeks to acquire and develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs. The company was founded by Eric Weisblum on July 13, 2010 and is headquartered in Englewood Cliffs, NJ.
Receive News & Ratings for Allbirds Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allbirds and related companies with MarketBeat.com's FREE daily email newsletter.
Allbirds (NASDAQ:BIRD – Get Rating) and Silo Pharma (NASDAQ:SILO – Get Rating) are both small-cap retail/wholesale companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.
Allbirds（纳斯达克股票代码：BIRD — 获取评级）和Silo Pharma（纳斯达克股票代码：SILO — Get Rating）都是小型零售/批发公司，但哪种投资更好？我们将根据两家企业的股息、收益、估值、机构所有权、风险、盈利能力和分析师建议进行比较。
Institutional & Insider Ownership
机构所有权和内部所有权
33.1% of Allbirds shares are held by institutional investors. Comparatively, 11.6% of Silo Pharma shares are held by institutional investors. 31.9% of Allbirds shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Allbirds的33.1％股份由机构投资者持有。相比之下，11.6％的Silo Pharma股票由机构投资者持有。Allbirds的31.9％的股票由公司内部人士持有。强大的机构所有权表明对冲基金、捐赠基金和大型基金经理认为股票有望实现长期增长。
Profitability
盈利能力
This table compares Allbirds and Silo Pharma's net margins, return on equity and return on assets.
该表比较了Allbirds和Silo Pharma的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Allbirds | -27.97% | -19.91% | -16.36% |
| Silo Pharma | -4,622.68% | -35.46% | -31.26% |
| 净利润 | 股本回报率 | 资产回报率 | |
| 所有鸟 | -27.97% | -19.91% | -16.36% |
| 筒仓制药 | -4,622.68% | -35.46% | -31.26% |
Analyst Recommendations
分析师建议
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Allbirds | 0 | 7 | 6 | 0 | 2.46 |
| Silo Pharma | 0 | 0 | 0 | 0 | N/A |
| 卖出评级 | 保持收视率 | 买入评级 | 强劲的买入评级 | 评分分数 | |
| 所有鸟 | 0 | 7 | 6 | 0 | 2.46 |
| 筒仓制药 | 0 | 0 | 0 | 0 | 不适用 |
Allbirds presently has a consensus price target of $7.15, suggesting a potential upside of 121.48%. Given Allbirds' higher possible upside, equities research analysts clearly believe Allbirds is more favorable than Silo Pharma.
Allbirds目前的共识目标价为7.15美元，这表明潜在的上涨空间为121.48％。鉴于Allbirds可能更高的上行空间，股票研究分析师显然认为Allbirds比Silo Pharma更有利。
Earnings and Valuation
收益和估值
This table compares Allbirds and Silo Pharma's gross revenue, earnings per share and valuation.
该表比较了Allbirds和Silo Pharma的总收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Allbirds | $310.81 million | 1.55 | -$45.37 million | ($0.61) | -5.30 |
| Silo Pharma | $70,000.00 | 137.26 | $3.90 million | N/A | N/A |
| 总收入 | 价格/销售比率 | 净收入 | 每股收益 | 市盈率 | |
| 所有鸟 | 3.1081 亿美元 | 1.55 | -4537 万美元 | (0.61 美元) | -5.30 |
| 筒仓制药 | 70,000.00 美元 | 137.26 | 390 万美元 | 不适用 | 不适用 |
Silo Pharma has lower revenue, but higher earnings than Allbirds.
Silo Pharma的收入较低，但收益高于Allbirds。
Summary
摘要
Allbirds beats Silo Pharma on 8 of the 10 factors compared between the two stocks.
与两只股票相比，Allbirds在10个因素中的8个方面击败了Silo Pharma。
About Allbirds
Allbirds
(Get Rating)
（获取评分）
Allbirds, Inc. manufactures and sells footwear and apparel products for men and women. It offers shoes, such as running shoes, everyday sneakers, high-tops, slip-ons, boat shoes, flats, weather repellent shoes, and sandals. The company's apparel products include activewear, tops, bottoms, dresses, sweaters, underwear, and socks. It sells its products through its retail stores in the United States and internationally, as well as online. Allbirds, Inc. was formerly known as Bozz, Inc. Allbirds, Inc. was incorporated in 2015 and is based in San Francisco, California.
Allbirds, Inc. 生产和销售男士和女士鞋类和服装产品。它提供鞋子，例如跑步鞋、日常运动鞋、高帮鞋、懒人鞋、船鞋、平底鞋、防风雨鞋和凉鞋。该公司的服装产品包括运动服、上衣、下装、连衣裙、毛衣、内衣和袜子。它通过其在美国和国际上的零售商店以及在线销售其产品。Allbirds, Inc. 前身为 Bozz, Inc. Allbirds, Inc. 成立于 2015 年，总部位于加利福尼亚州旧金山。
About Silo Pharma
关于 Silo Pharma
(Get Rating)
（获取评分）
Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in merging traditional therapeutics with psychedelic research. It seeks to acquire and develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs. The company was founded by Eric Weisblum on July 13, 2010 and is headquartered in Englewood Cliffs, NJ.
Silo Pharma, Inc. 是一家处于发展阶段的生物制药公司，致力于将传统疗法与迷幻研究相结合。它旨在从大学和研究人员那里获得和发展知识产权或技术权利，以治疗罕见疾病，包括使用迷幻药物。该公司由埃里克·韦斯布鲁姆于2010年7月13日创立，总部位于新泽西州恩格尔伍德克利夫斯。
Receive News & Ratings for Allbirds Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allbirds and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Allbirds 每日的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Allbirds及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧